Current and Emerging Roles of Whole-Body PET Imaging in Breast Cancer

Abstract Archives of the RSNA, 2011

MSVM21-13

Current and Emerging Roles of Whole-Body PET Imaging in Breast Cancer

Multisession Courses

Presented on November 28, 2011
Presented as part of MSVM21: Breast/Nuclear Medicine/Molecular Imaging Series: Breast Imaging in the Era of Molecular Medicine

Participants

Richard L. Wahl MD, Presenter: Patents, Naviscan, Inc Patents, GlaxoSmithKline plc Patents, Spectrum Pharmaceuticals, Inc Research Consultant, GlaxoSmithKline plc Research Consultant, Nihon Medi-Physics Co, Ltd Research support, General Electric Company Research support, Molecular Insight Pharmaceuticals, Inc Research support, Cell Point LLC

LEARNING OBJECTIVES

1) Recognize at least three physiological alterations in breast cancer, which can be imaged using PET. 2) Recognize at least one histology of breast cancer which can be falsely negative on PET imaging using FDG. 3) Recognize at least one cause of false-positive PET scans in breast cancer. 4) Be aware of typical changes in glucose metabolism and tumor size associated with successful neoadjuvant chemotherapy of breast cancer.

Cite This Abstract

Wahl, R, Current and Emerging Roles of Whole-Body PET Imaging in Breast Cancer. Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11033092.html